Reference

Salmeterol does not cause tolerance during long-term asthma therapy

Salmeterol does not cause tolerance during long-term asthma therapy. Arledge, Teresa E. 89365-50-4 are also occured in this study.; Liddle, Roger; Stahl, Edmundo; Rossing, Thomas H. (Glaxo Wellcome Inc., Research Triangle Park, NC, USA). Journal of Allergy and Clinical Immunology, 98(6, Pt. 1), 1116-1119 (English) 1996 Mosby-Year Book. CODEN: JACIBY. ISSN: 0091-6749. DOCUMENT TYPE: Journal CA Section: 1 (Pharmacology) In this report, representing results from the largest database of patients receiving salmeterol in clin. studies in the USA, the authors support the growing body of evidence that patients with asthma do not show any loss of bronchodilator effect after regular exposure to this b2 agonist. .

A twelve-week comparison of salmeterol and salbutamol in the treatment of mild-to-moderate asthma: a Canadian multicenter study

A twelve-week comparison of salmeterol and salbutamol in the treatment of mild-to-moderate asthma: a Canadian multicenter study.Some chemicals with cas registry numbers like 89365-50-4 and 18559-94-9 are also used. Boulet, Louis-Philippe; Laviolette, Michel; Boucher, Serge; Knight, Allan; Hebert, Jacques; Chapman, Kenneth R. (Centre de Pneumologie, Hopital Laval, Sainte-Foy, QC G1V 4G5, Can.). Journal of Allergy and Clinical Immunology, 99(1, Pt. 1), 13-21 (English) 1997 Mosby-Year Book. CODEN: JACIBY. ISSN: 0091-6749. DOCUMENT TYPE: Journal CA Section: 1 (Pharmacology) A long-acting inhaled bronchodilator that is both well tolerated and effective could allow for improved control of both daytime and nighttime symptoms in patients with asthma who use frequent as-needed short-acting bronchodilators despite antiinflammatory treatment. We compared the efficacy and safety of inhaled salmeterol, 50 mg twice daily, with inhaled salbutamol, 200 mg four times daily, delivered through a metered-dose inhaler for 3 mo in a multicenter, randomized, double-blind, parallel-group study of 228 patients (aged 12 to 76 yr) with mild-to-moderate asthma. A single morning dose of salmeterol produced improvement in FEV1 that was significantly greater (p ￡ 0.012) than that produced by two doses of salbutamol (taken 6 h apart) when patients were assessed 3 to 6 h and 10 to 12 h after the dose. This greater bronchodilation was present on day 1 of the study and after 4, 8, and 12 wk of regular treatment. Over the 12 wk, compared with salbutamol, salmeterol treatment was assocd. with a greater mean improvement in morning peak expiratory flow (35 L/min vs -3 L/min, p < 0.001), a higher percentage of days with no symptoms (29% vs 15%; p = 0.012), and a higher percentage of nights with no awakenings (14% vs -1%; p < 0.001). Adverse events were similar for both treatments. In this study salmeterol, 50 mg twice daily, was well tolerated and more effective than salbutamol, 200 mg four times daily, in improving symptoms and lung function in patients with mild-to-moderate asthma. .